Ex vivo engineering of hematopoietic stem cells using RNA-LNPs for cell and gene therapies
Sponsor
Delivering nucleic acids using lipid nanoparticles (LNP) to target cells has tremendous potential to enable new cell and gene therapies. In this webinar, we'll share insights on an innovative genomic medicines toolkit, focusing on technologies that streamline the development of RNA-LNP medicines.
We're excited to introduce you to off-the-shelf reagents designed specifically for producing RNA-LNPs optimized for hematopoietic stem cells (HSC), alongside the NanoAssemblr™ manufacturing platform equipped with NxGen™ technology. This platform can enable rapid development and scale-up production of RNA-LNPs. Through this presentation, we will walk you through data for ex vivo hematopoietic stem cell therapies showcasing how LNPs serve as a vehicle for RNA delivery for the transient expression of therapeutic genes and gene-editing nucleases.
Join us in this webinar to learn more about:
- How RNA-LNPs are being used to develop the next-generation of HSC therapies
- How to perform highly efficient gene editing in CD34+ HSCs
- Seamless integration of LNPs in CD34+ HSC cell manufacturing workflow
- Scaling up ex vivo cell therapy from discovery to preclinical using the NanoAssemblr™ LNP manufacturing platform
SPEAKERS
You might also like
Development of an automated AAV capsid titer assay on a high-throughput platform
Quickly and accurately measure key analytical attributes of viral vectors with macro mass photometry
Extracellular vesicles: setting-up the path to IND with advanced characterization packages
Optimizing bioprocess purification: effective nucleic acid removal in high salt environments
